RECORDATI GROUP

Pharma

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 4 drugs with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

3 drugs in development

Phase 31

Phase 21

Preclinical1

By Therapeutic Area

top 3

Cardiovascular

125%

Metabolic & Endocrine

125%

Hematology

125%

R&D Momentum

40/100

Pipeline Velocity

11/100

Trial Completion Rate

76/100

Pipeline Concentration

25/100

Pipeline Freshness

57/100

Strategic Signals

↗Active in Cardiovascular but thin pipeline — potential licensing opportunity

Activity

Key Events

Dec 1, 2025TrialStudy in Healthy Subjects to Investigate the Relative Bioavailability and Safety of Pasireotide After Single Subcutaneous Dose Administration Using a Reusable ServoPen With Cartridge as Compared to Administration Using a Syringe Drawn From an Ampule

Jan 4, 2024TrialPasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia

Jan 16, 2023TrialOsilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome

Jun 30, 2022TrialAn Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics

Jun 13, 2022TrialNon-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome

Feb 21, 2022TrialReal-life Observational Study of Cancer Pain Management With Methadone

Apr 28, 2021TrialPharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome

Mar 31, 2021TrialSiltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease

4 more events

Nov 13, 2020TrialSILtuximab in Viral ARds (SILVAR) Study

Oct 13, 2020TrialREC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients

Sep 1, 2020TrialCystadrops in Pediatric Cystinosis Patients From Six Months to Less Than Two Years Old (SCOB2)

Mar 6, 2020FDAIsturisa — ISTURISA

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

9 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Valchlor5 patentsMar 7, 2026 IsturisaAug 23, 2026 Signifor2 patentsOct 25, 2026 SigniforMay 23, 2028 IsturisaMar 27, 2029 ValchlorJul 8, 2029 Isturisa2 patentsJan 13, 2031 NeoprofenMar 2, 2032

1 more

Isturisa2 patentsJul 6, 2035

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

LCI699Phase 2

Hypertension

LCI699Phase 2

Hematology

Cold Agglutinin Disease

SutimlimabPreclinical

Metabolic & Endocrine

Hyperaldosteronism

LCI699Phase 2

Unknown / Other

Propionic Acidemia

CarbagluPhase 3

Regulatory

Regulatory Timeline

19822 events

FDAJan 1

Cosmegen — COSMEGEN

Application NDA050682 (NDA)

FDAJan 1

Valchlor — MUSTARGEN

Application NDA006695 (NDA)

19911 event

FDAJan 30

Chemet — CHEMET

Application NDA019998 (NDA)

19961 event

FDAOct 25

Cystadane — CYSTADANE

Application NDA020576 (NDA)

20062 events

FDAApr 13

Neoprofen — NEOPROFEN

Application NDA021903 (NDA)

FDAApr 13

Neoprofen — NEOPROFEN

Application NDA021903 (NDA)

20101 event

FDAMar 18

Carbaglu — CARBAGLU

Application NDA022562 (NDA)

20121 event

FDADec 14

Signifor — SIGNIFOR

Application NDA200677 (NDA)

20131 event

FDAAug 23

Valchlor — VALCHLOR

Application NDA202317 (NDA)

20141 event

FDAApr 23

Sylvant — SYLVANT

Application BLA125496 (BLA)

20181 event

FDAJun 29

Signifor — SIGNIFOR LAR KIT

Application NDA203255 (NDA)

20201 event

FDAMar 6

Isturisa — ISTURISA

Application NDA212801 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)